The NCMAG Council makes decisions on the proposed use of cancer medicines.
These medicines uses are planned for review by NCMAG:
| Medicine | Use | Council meeting date | Planned publication date | ID number |
|---|---|---|---|---|
| Medicine Anastrozole | Use The primary prevention of breast cancer in post-menopausal women at moderate to high risk. On-label and off-patent use | Council meeting date 19 September 2024 | Planned publication date 24 October 2024 | ID number NCMAG113 |
| Medicine Raloxifene | Use The primary prevention of breast cancer in post-menopausal women at moderate to high risk whom anastrozole is unsuitable. Off-label use and off-patent medicine | Council meeting date 19 September 2024 | Planned publication date 24 October 2024 | ID number NCMAG114 |
| Medicine Tamoxifen | Use The primary prevention of breast cancer in women at moderate or high risk. On-label use and off-patent medicine | Council meeting date 19 September 2024 | Planned publication date 24 October 2024 | ID number NCMAG115 |
| Medicine Dasatinib | Use For the treatment of adult patients with newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukaemia. Off-label use and off-patent medicine | Council meeting date 20 June 2024 | Planned publication date 25 July 2024 | ID number NCMAG116 |
| Medicine Dasatinib | Use For the treatment of adult patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukaemia resistant or intolerant to prior therapy, including imatinib. Off-label use and off-patent medicine | Council meeting date 20 June 2024 | Planned publication date 25 July 2024 | ID number NCMAG117 |
| Medicine Trametinib | Use For patients with recurrent or progressive low grade serous ovarian carcinoma after at least 1 line of platinum-based chemotherapy. Off-label use | Council meeting date 19 September 2024 | Planned publication date 24 October 2024 | ID number NCMAG118 |
| Medicine Pomalidomide in combination with low-dose dexamethasone | Use For patients who have received at least one prior line of therapy that has included lenalidomide. Off-label use and pending off-patent status | Council meeting date 12 December 2024 | Planned publication date 16 January 2025 | ID number NCMAG119 |